NASDAQ$GDRX

GoodRx Holdings Inc. · Q4 2018 earnings

Q4 2018 earnings · · Investor relations

Headline financials

Total Revenue

$243M

No prior period
EPS (adj)

$0.12

No prior period
Capital Expenditures

$804K

No prior period
Free Cash Flow

$44.4M

No prior period
Net Income

$43.8M

No prior period
Operating Income

$77.3M

No prior period
Gross Profit

$250M

No prior period
Cash & Equivalents

$34.6M

No prior period
Stock-Based Comp

$1.76M

No prior period

Revenue & EPS history

GoodRx · Revenue · Quarterly

$243M

Q4 2018
Beat estimate in 7 of 9 quarters(78%)
ActualEstimate

Revenue by segment

GoodRx · $175M total across 3 segments · Q3 2023

  • Prescription Transactions
    $135M+3.2%
  • Subscription
    $23.2M-12.5%
  • Pharma Direct
    $15.9M-35.1%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2018

Historical avgQ4 2018

-5.3%

Avg return

Earnings day

-8.5%

Avg return

5 days after

-5.0%

Avg return

30 days after

37%

10 / 27 earnings

Positive

+29.1%

Q4 2023

Best reaction

-37.4%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.4%+10.5%+3.5%
Q4 2025-19.5%-15.5%-20.8%
Q3 2025+1.8%-6.1%-16.9%
Q1 2025+11.9%+13.5%+7.7%
Q4 2024+1.8%-4.5%-8.0%
Q3 2024-20.0%-23.1%-19.6%
Q2 2024-16.3%-20.2%-10.5%
Q1 2024-13.3%-12.6%+12.4%
Q4 2023+29.1%+17.6%+9.7%
Q3 2023-12.4%-8.8%+9.1%
Q2 2023-5.6%-14.1%-29.3%
Q1 2023+7.0%+10.9%+17.5%
Q4 2022+5.6%+13.6%+14.2%
Q3 2022-21.5%+10.4%+0.8%
Q2 2022+10.5%+4.1%-12.6%
Q1 2022-37.4%-30.1%-43.5%
Q4 2021-36.3%-39.2%-27.9%
Q3 2021-5.7%-5.1%-5.4%
Q2 2021+20.0%+13.3%+37.1%
Q1 2021+5.1%+2.4%+24.8%
Q4 2018-10.5%-14.2%-7.9%
Q2 2020-3.9%-7.8%-1.2%
Q4 2020-3.9%-7.8%-1.2%
Q1 2020-7.3%-29.1%-16.5%
Q3 2019-7.3%-29.1%-16.5%
Q3 2020-7.3%-29.1%-16.5%
Q4 2019-7.3%-29.1%-16.5%
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro